MedTrace Logo

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCT00169988 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-12-17

No results posted yet for this study

Summary

The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.

Conditions

  • Prodromal Schizophrenia
  • Psychotic Disorders

Interventions

DRUG

risperidone

DRUG

sertraline-primary

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Janssen Pharmaceutica N.V., Belgium

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Northwell Health

    lead OTHER

Principal Investigators

  • Barbara A Cornblatt, PhD · Long Island Jewish Medical Center (LIJMC)

  • Christoph U Correll, MD · LIJMC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169988 on ClinicalTrials.gov